News
The UK's drugs regulator yesterday issued a proposal that would see GlaxoSmithKline’s migraine drug Imigran/Imitrex (sumatriptan) and AstraZeneca’s Zomig (zolmitriptan) switched from prescription-only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback